Sana Biotechnology, Inc. (SANA): Shareholders' Equity
$160.88M
As of 2025-12-31
$154.57M
As of 2026-06-30
-31.4%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $160.88M | -35.8% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $250.50M | -12.9% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $287.51M | -42.4% | 2026-03-03, Balance as of period end |
| 2022-12-31 | $499.31M | -31.5% | 2025-03-17, Balance as of period end |
| 2021-12-31 | $728.50M | n/m | 2024-02-29, Balance as of period end |
| 2020-12-31 | -$421.18M | n/m | 2023-03-16, Balance as of period end |
| 2019-12-31 | -$142.54M | n/a | 2022-03-16, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $160.88M | -35.8% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $292.54M | -30.7% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $245.49M | -33.4% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $354.97M | n/m |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $408.73M | -30.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $233.06M | +4.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $102.73M | -60.4% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | -$164.31M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗